Navigation Links
WHOs Plan of Global Stockpile of Bird Flu Vaccine Gathers Momentum

The World Health Organization (WHO) announced that it is working with vaccine manufacturers to move ahead on plans to create a global stockpile of vaccine for the H5N1 avian influenza virus.

The announcement follows a request by the World Health Assembly in May for WHO to establish an international stockpile of H5N1 vaccine.

WHO has also welcomed the announcement by GlaxoSmithKline that it would contribute to the H5N1 global vaccine stockpile. Omninvest of Hungary, Baxter and sanofi pasteur have also indicated their willingness to make some of their H5N1 vaccine available.

"This is another significant step towards creating a global resource to help the world and especially to help developing countries in case of a major outbreak of H5N1 avian influenza," said Dr Margaret Chan, WHO Director-General.

"WHO welcomes this contribution from the vaccines industry and is also working with countries to develop capacity for the production of influenza vaccines," he added.

Further work is needed on detailed operational planning for the stockpile, including how and under which conditions it will be deployed, as well as regulatory aspects of the vaccine.

Besides developing a stockpile of H5N1 vaccine, other measures being taken by WHO to prepare for a potential influenza pandemic include rapid containment plans to stop a pandemic using public health measures and anti-virals; and assistance to countries to increase vaccine production capacity, including research and promoting the transfer of technology to developing countries.


'"/>




Page: 1

Related medicine news :

1. SARS-Free Taiwan to Mark End Phase of Global Fight
2. Prevent Global Warming by Becoming A Vegetarian
3. India To March Ahead in The Global HealthCare Competition
4. Global Outbreak Of Bird Flu Warning By Chinese Scientist
5. TWO India Doctors Listed in TIME for Contribution to Global Health
6. Global Hospitals coming to city of Joy
7. John Hopkins CGHH program provides Global Health education
8. Ban on Global fund lifted in Uganda
9. Global Warming Could Cause 5 Million Illnesses: WHO
10. Global Health Bonds to Improve Health Care Facilities for the Underprivileged.
11. Skin Cancer Research To Go Global
Post Your Comments:
(Date:10/3/2008)...- Inc. Magazine recently included,Connolly Consult...ing,private companies in the country. The list is ...segment of the economy -- America,s,independent-mi...ies,represent the backbone of the U.S. economy., ...03/NY36880LOGO ), Connolly Consulting,s consiste...
(Date:10/3/2008)... Discrimination; Recognizes,Importance of Mental H.../PRNewswire-USNewswire/ -- Mental Health,America t...approval of a,mental health parity legislation tha...ion against Americans with mental health and subst...lans., The legislation, which recognizes the impo...
(Date:10/3/2008)...search Foundation(R) Collection of, Bouquets to T...Research, LOS ANGELES, Oct. 3 /PRNewswire/ -- Tel...g only hand-arranged, hand-delivered floral,arrang...nth-long,collaboration with The City of Hope, John... Cancer Center in southern California and national...
(Date:10/3/2008)...- As the population ages, a big,question employers...e the,financial crunch of an illness?", In most c...eck to,paycheck and now need two incomes to provid... spouses becomes critically ill and unable to work...ut the healthy,employee/spouse is strained by the ...
Breaking Medicine News(10 mins):Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 3Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 2Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 3Health News:Can Your Employees Survive the Financial Crunch of an Illness? 2
...s of hand-foot-mouth disease were reported in the ... of disaster relief George Chan Hong Nam said that...e days, bringing this year's total to more than 1,...uld not take this lightly, as the consequences can...
...ing pregnancy and childbirth are less likely to in...ing activities such as playing with their newborns...irst of its kind to analyze the impact of mother’s...practices, post partum. The researchers analyzed ...
...efects is improved by incorporation of folic acid ... known that folic acid supplementation during preg...th defects such as spina bifida, anencephaly etc. ...f consumption of folic acid fortified grains on ne...
... that the dreaded bird flu had made an entry into ...was confirmed that a cat had died of bird flu. Sin...sures to ward off the disease. // Federal Agricult...hofer has said that cats in the region of the bird...
Other Medicine News:Health News:Depressive Mothers Do Not Play Enough With Their Infants 2
(Date:10/2/2008)... STOCKHOLM, October 2 /- Athera Biot...unced today that they have entered into a,collabor...cts for the,prevention or treatment of cardiovascu...lows the recent publication of work by Athera,scie...e of the Karolinska,Institutet. The research links...
(Date:10/2/2008)... Data Indicate Dual Modes of Action and Synergy...rstCall/ -- Access Pharmaceuticals, Inc.,(OTC Bull...eclinical,studies on Angiolix showing that by bloc...enic effect as well as a direct anti-proliferative...s of human breast cancer (MX-1),Angiolix had a si...
(Date:10/1/2008)...ta support the therapeutic potential of Amylin,s i...to obesity pharmacotherapy, SAN DIEGO, Oct. 1 /PR.... (Nasdaq: AMLN ) today announced that new data f...ed at the 2008 Annual Scientific Meeting of The,Ob...Society,s annual,meeting is one of the largest and...
(Date:10/1/2008)...Intermezzo(R) (zolpidem tartrate sublingual lozeng...ly for use in the middle of the night when ...sleep, PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ ...ld specialty pharmaceutical company, announced tod...DA) to the U.S. Food and,Drug Administration (FDA)...
Breaking Medicine Technology:Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 2Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 3Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 4Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 6Experts discuss climate change during UH lecture series 5081 1Experts discuss climate change during UH lecture series 5081 2Telik Announces Receipt of Nasdaq Notice 7927 1Telik Announces Receipt of Nasdaq Notice 7927 2Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment 7926 1Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment 7926 2Army can boost mission success by better managing 5076 1Army can boost mission success by better managing 5076 2Army can boost mission success by better managing 5076 3Army can boost mission success by better managing 5076 4
...trates Continued Safety for XIENCE V with No,Late ...ac Events,Out to Three Years, BARCELONA, Spain, Ma...ta from the SPIRIT FIRST trial demonstrated no,add...o late stent,thrombosis in patients treated with e...onary Stent System or its MULTI-LINK,VISION(R) met...
...2007 /PRNewswire-FirstCall/ -- Forest,Laboratories...d,that preliminary top-line results from a 1,196 p...ebo-controlled pivotal Phase III,study demonstrate...milnacipran as a treatment of fibromyalgia syndrom...to review initial top-line,results and further ana...
Other Medicine Technology:Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 2Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 3Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6
The AccuSonic A-scan makes it easy to obtain extreme accuracy and improved patient outcomes. Obtain accurate measurements with industry leading signal acquisition and processing.
The UD-1000 incorporates the latest ultrasound technology for eyecare specialists. It is the ideal choice for your modern diagnostic laboratory. The UD-1000 combines a powerful B-sector scan system w
The UD-6000 combines all the functions of modern ultrasound diagnostics used in ophthalmology: The latest generation high resolution A/B-sector scanner, a diagnostic A-mode scanner with an optional p
ISYSTEM-ABDv2™A/B Scan unit. True Geometry With Stepped Zoom, Pan, Freeze Frame, Post Image Processing.
Medicine Products: